Download PDF
Onkologische Welt 2017; 08(06): 254-255
DOI: 10.1055/s-0038-1639652
DGHO 2017 Stuttgart
Schattauer GmbH

Welche Marker helfen bei der Therapiewahl?

Metastasiertes kastrationsresistentes Prostatakarzinom
Helmine Braitmaier Dr.
Further Information

Publication History

Publication Date:
10 March 2018 (online)

Also available at
   Permissions and Reprints

Zur Behandlung des metastasierten kastrationsresistenten Prostatakarzinoms (mCRPC) haben Ärzte in Deutschland mit Docetaxel, Cabazitaxel, Abirateron, Enzalutamid und Radium-223 verschiedene Optionen zur Verfügung. Klinische Marker, die bei der Therapiewahl helfen könnten, sind bisher nicht ausreichend validiert. Mit aktuellen Erkenntnissen zu neuen Biomarkern beschäftigte sich ein Symposium auf dem DGHO 2017.

 

  • Literatur

  • 1 Droz JP. et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15 (09) e404-e414.
    CrossrefPubMedSearch in Google Scholar
  • 2 Gillessen S. et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2017 Vorabpublikation, doi: 10.1016/j.eururo.2017.06.002
    PubMedSearch in Google Scholar
  • 3 Oudard S. et al. Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. J Clin Oncol. 2017 Vorabpublikation, doi: 10.1200/JCO.2016.72
    PubMedSearch in Google Scholar
  • 4 Fitzpatrick JM. et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 2014; 50 (09) 1617-1627.
    CrossrefPubMedSearch in Google Scholar
  • 5 Fizazi K. et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. NEJM 2017; 377 (04) 352-360.
    CrossrefPubMedSearch in Google Scholar
  • 6 Antonorakis ES. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. NEJM 2014; 371 (11) 1028-1038.
    CrossrefPubMedSearch in Google Scholar
  • 7 Antonorakis ES. et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With Firstand Second-Line Abiraterone and Enzalutamide. . J Clin Oncol 2017; 35 (19) 2149-2156.
    CrossrefPubMedSearch in Google Scholar
  • 8 Robinson D. et al. Integrative Clinical Genomics of Advanced Prostate Cancer. Cell 2015; 161: 1215-1228.
    CrossrefPubMedSearch in Google Scholar
  • 9 Ross JS. et al. Correlation of primary tumor prostatespecific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9(17): 6357–6362Fendler WP et al: 68Ga-PSMA-11 PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 2017; 44: 1014-1024.
    Search in Google Scholar